A novel anti‐c‐Kit antibody–drug conjugate to treat wild‐type and activating‐mutant c‐Kit‐positive tumors

c‐Kit overexpression and activating mutations, which are reported in various cancers, including gastrointestinal stromal tumor (GIST), small‐cell lung cancer (SCLC), acute myeloid leukemia, acral melanoma, and systemic mastocytosis (SM), confer resistance to tyrosine kinase inhibitors (TKIs). To ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jin‐Ock, Kim, Kwang‐Hyeok, Baek, Eun Ji, Park, Bomi, So, Min Kyung, Ko, Byoung Joon, Ko, Han‐Jik, Park, Sang Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936518/
https://www.ncbi.nlm.nih.gov/pubmed/34407310
http://dx.doi.org/10.1002/1878-0261.13084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936518/
https://www.ncbi.nlm.nih.gov/pubmed/34407310
http://dx.doi.org/10.1002/1878-0261.13084

Ejemplares similares